Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)

Summary

Aortic stiffness is an important imaging biomarker of vascular aging. The ascending aorta is the most elastic segment, and it is excluded by reference non-invasive method carotid to femoral pulse wave velocity (PWV). We propose to use laser-doppler vibrometry (LDV) to record superficial vibrations generated by cardiac activity and arterial pulses for measuring heart carotid PWV, a surrogate for ascending aorta.

The trial aims to demonstrate the equivalence between heart-carotid PWV made by laser-doppler vibrometry (LDV) with the reference MRI measurement (4D-FLOW MRI).

As secondary objectives, A) we aim to assess the reproducibility of LDV, compared with MRI, B) show that aortic stiffness measured by LDV fulfils international recommendations, C) to study the association between PWV and age or other cardiovascular risk factors, D) assess the acceptability of the measurement. For this, we include 100 consecutive patients, 50 women, 50 men, scheduled for clinically indicated thoracic aorta MRI.

Conditions

• Hypertension
• Aortic Aneurysm
• Bicuspid Aortic Valve
• Marfan Syndrome
• Aortic Dilatation

Interventions

DEVICE

Laser doppler vibrometry (LDV), heart(cordium) carotid pulse wave velocity (ccPWV)

Patients scheduled for thoracic aorta MRI will have LDV measurement of ccPWV. Both techniques will be compared

PROCEDURE

Blood pressure and heart rate measurement

To all patients: \- blood pressure and heart rate will be measured

DEVICE

carotid to femoral PWW measurement

To all patients: \- carotid to femoral PWW will be measured by LDV and tonometry for comparison

PROCEDURE

Questionnaire completion

All patients will complete a questionnaire of acceptability

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France

  lead OTHER_GOV

Principal Investigators

• Pierre Boutouyrie · Hôpital Européen Georges-Pompidou

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-03-13

Primary Completion

2024-06-19

Completion

2024-06-19

Countries

• France

Study Locations